28 April 2021>: Articles
Glycemic Profile of Intravenous Dexamethasone-Induced Hyperglycemia Using Continuous Glucose Monitoring
Unusual clinical course, Unusual or unexpected effect of treatment, Educational Purpose (only if useful for a systematic review or synthesis)
Fan Zhang A* , Jocelyne G. Karam ADOI: 10.12659/AJCR.930733
Am J Case Rep 2021; 22:e930733
Figure 1. The triphasic glycemic pattern following chemotherapy which contained IV Dexamethasone (arrow). (A) Four days CGM showed a steady state of hyperglycemia reached within 3 h and lasting around 23-35 h, with no association to meal intake, followed by a transient BG improvement for 14–21 h, and ending with another hyperglycemic plateau of 7–13 h on day 3 after chemotherapy. (B) Average glucose tracing of CGM from 23 cycles showed the average glucose tracing and standard deviation. (* Normal/low glucose between 2 hyperglycemia phases; ** hyperglycemia plateau shape similar to the baseline.)